THE ROLE OF ANDROGENS in cardiovascular functions is controversial, and both beneficial and detrimental effects of androgens have been reported (25, 33, 55) . Epidemiological studies suggest that males are at a greater risk for cardiovascular disease compared with age-matched females during their reproductive years (25, 33, 55) . This sex difference has been postulated to be attributable to the estrogen-protective and/or androgen-detrimental effects on the cardiovascular system. However, the estrogen-protective effect has not been confirmed in large prospective studies such as the Women's Health Initiative study (16, 37) , the Coronary Drug Project (48) , and The Veterans Administration Cooperative Urological Research Group study (49, 50) , which all have shown that administration of estrogens in either women or men display a detrimental effect on the cardiovascular system. Similarly, the detrimental effect of androgens on the cardiovascular system is not supported by large prospective clinical studies, and actually there are growing evidences supporting the protective/beneficial actions of androgens in the cardiovascular system (33) . Multiple large prospective clinical studies (19, 21, 33, 41 ) and a recent meta-analysis (20) have shown that testosterone insufficiency in men is associated with increased risk of cardiovascular diseases and mortality. In addition, studies in both humans and animals have demonstrated that androgens possess such beneficial effects as anti-angina (7, 27, 28, 36) , anti-atherosclerotic effects (27) , improvement of the exercise-induced ST-segment depression in men with coronary disease (15) , inducement of both endothelium-dependent and -independent vasorelaxation (2, 18) , and increased coronary blood flow (4, 27) . The cellular and molecular mechanisms of these beneficial androgen actions are poorly understood although intensively investigated in recent years. A plausible mechanism is that androgens may modulate endothelial functions.
Endothelium, interacting with circulating cells present in the vascular walls and on the walls of smooth muscle cells, plays an essential role in the control of vascular permeability, vascular tone, blood clotting, blood flow, and angiogenesis (1, 13, 51) . Endothelial cells are the main responders to the changes in blood composition and blood flow and play a central role in the mechanisms underlying the development of the vascular disorders. Endothelial damage and/or dysfunction may lead to formation of blood clotting, plaques, and atherosclerosis and cause an imbalance between vasodilating and vasoconstricting substances produced by or acting on the vascular wall increasing arterial stiffness (1, 13, 51) . Thus modulation of endothelial functions may be a promising mechanism of androgen actions in the cardiovascular system.
Previous studies have shown that dihydrotestosterone (DHT), a potent endogenous androgen converted from testosterone by 5␣-reductase isozymes (58) , increased [ 3 H]thymidine incorporation in human umbilical venous endothelial cell line (HUVEC), ECV304, by increasing the activity of creatine kinase and mitogen-activated protein kinase activity via classical genomic pathway (43, 45) . Because an endothelial damage/dysfunction in the arteries is a major pathogenic factor of atherosclerosis and hypertension (5, 9) , it is imperative to reveal the role of androgens in arterial endothelial cells. In the present study, we have examined the effects of androgens on cell proliferation and gene expression and elucidated the molecular mechanism of androgen induction of cell growth in primary human aortic endothelial cells (HAECs). Our results indicate that DHT interacting with androgen receptor (AR) induces cell proliferation through upregulation of vascular endothelial growth factor (VEGF) and cyclin gene expression in HAECs.
MATERIALS AND METHODS
Reagents. Testosterone, DHT, 17␤-estradiol, roscovitine, and SU-5416 were purchased from Sigma (St. Louis, MO) and dissolved in absolute ethanol at a stock concentration of 10 Ϫ2 mol/l. Casodex (bicalutamide) was obtained from Toronto (North York, ON, Canada). The SuperSript III Platinum1 Two-Step qRT-PCR Kit was obtained from Invitrogen (Carlsbad, CA). Antibodies against AR and ␤-actin were obtained from Santa Cruz Biotechnology (sc-7305; Santa Cruz, CA) and Sigma, respectively.
Cell cultures. Two independent primary HAECs were purchased from Lonza Walkersville (Walkersville, MD) and Invitrogen. These cells were grown in complete medium containing endothelial growth medium (EGM)-2 (Lonza), 2% fetal bovine serum, and supplements with growth factors (hydrocortisone, human epidermal growth factor, bovine brain extract, and gentamicin/amphotericin-B) as instructed by the manufacturer. Cells were maintained at 37°C in a humidified atmosphere contained in a 5% CO 2 incubator. Endothelial cells with less than five passages in the laboratory were used for the present experiments. All experiments were carried out in the experimental medium containing EGM phenol red-free medium (Lonza), 2% stripped fetal bovine serum (Gemini Bio-Products, Calabasas, CA), and gentamicin/amphotericin-B, and each experiment was repeated at least two times.
Cell proliferation assay. For the determination of viable cell number, HAECs were plated in 96-well plates at a density of ϳ2,500 -3,000 cells/well in the experimental medium. Twenty-four hours after plating, cells were treated with various agents as indicated in each experiment. The number of viable cells was determined using CellTiter Aqueous One Solution Cell Proliferation Assay kit from Promega (Madison, WI) according to the manufacturer's instruction.
Bromodeoxyuridine incorporation assay. HAECs were seeded in 96-well plates and treated with various drugs as indicated in each experiment for 48 h. At the end of treatment, bromodeoxyuridine (BrdU) incorporation was assayed by incubating cells with BrdU for 1 h using a BrdU Cell Proliferation Assay kit from Calbiochem (San Diego, CA) according to the instruction from the manufacturer.
Western blot analysis. Western blot was carried out as previously described (47, 59 ) with minor modifications. Briefly, HAECs treated with various agents were harvested, and total cellular proteins were extracted using a lysis buffer (62.5 mmol/l Tris·HCl, pH 6.8, 100 mmol/l dithiothreitol, 2% SDS, 10% glycerol). The protein concentrations were then determined using the Bio-Rad Protein Assay following the manufacturer's instruction (Bio-Rad, Hercules, CA). Equal amounts of proteins were fractionated on a 15% SDS-PAGE and transferred to a PVDF membrane (Amersham Pharmacia Biotech, Piscataway, NJ). The blots were blocked with TBST buffer (500 mmol/l NaCl, 20 mmol/l Tris·HCl, pH 7.4, and 0.1% Tween 20) containing 5% nonfat dry milk (Bio-Rad Laboratories) and then incubated with a specific primary antibody in TBST buffer containing 5% nonfat dry milk overnight at 4°C. Following secondary antibody incubation, the signal was visualized using the SuperSignal West Pico Chemiluminescent kit (Pierce Biotechnology, Rockford, IL) and exposed to Kodak X-Max film. ␤-Actin was used as an internal control by incubating a specific antibody against ␤-actin with the same membrane by stripping the membrane after the first blot. The specific signals of AR and ␤-actin were quantitated using the Image J software. The AR levels were expressed as fold of control after normalizing the internal ␤-actin level.
Real time RT-PCR. Real-time PCR was performed using the comparative C T method according to the instructions of the manufacturer on the ABI Prism 7900 Sequence Detection System (PE Applied Biosystems, Foster City, CA) in the institutional core facility as described (35) . Briefly, total cellular RNA was isolated from harvested cells using TriPure Isolation Reagent (Roche Diagnostics, Indianapolis, IN). RNA samples were subjected to a two-step realtime RT-PCR using SuperSript III Platinum Two-Step qRT-PCR Kit. Real-time PCR conditions were set according to the protocol from Invitrogen. PCR primers used are listed in Table 1 . GAPDH was used as an internal control. The difference between each sample was calculated by following the instructions of the manufacturer (PE Applied Biosystems), and the data are expressed as fold of the corresponding control group.
Small-interference RNA constructs and transfection. On the basis of the sequences of the human AR (GenBank accession no. NM_000044) and human VEGFA gene (GenBank accession no. NM_000006.10), custom stealth RNAi oligos (Invitrogen) at 21-25 base pairs in length were designed. Specifically, the sequences used were 5=-ACCGAGGAGCUUUCCAGAAUCUGUU-3= for AR, and 5=-GGAGUACCCUGAUGAGAUCTT-3= for VEGF. A nonspecific control small-interference RNA (siRNA) (5=-CCAUGGCGCCAAU-UCCAAACAGUUU-3=) was included in all siRNA experiments. All siRNA transfections were performed using Lipofectamine 2000 (Invitrogen) following the manufacturer's instruction. Briefly, HAECs were seeded in a 96-well plate at a density of 3,000 cells/well in EGM phenol red-free medium containing 2% stripped fetal bovine serum without antibiotics. Twenty-four hours later, when cells were attached to the plate, the cells were transfected with various concentrations of siRNA using 0.25 l of Lipofectamine 2000 in a total volume of 150 l OPTI-MEM medium (Invitrogen) per well. Sixteen hours after transfection, transfection reagents were removed, and cells were treated with various hormones for 48 h as indicated in each experiment. The number of viable cells, BrdU incorporation, and gene expression were determined at the end of experiments. The knockdown of AR was verified by Western blot analysis and VEGFA knockdown by analyzing VEGF concentration in culture media.
Determination of VEGF concentration in cell culture media. The levels of VEGF in cell culture media were determined by electrochemiluminescence detection using a MSD 96-Well Multi-Array Human VEGF Tissue Culture Assay kit from the Meso Scale Discovery (Gaithersburg, MD) according to the manufacturer's instruction. This assay has no significant cross activity (Ͻ0.6%) to basic fibroblast growth factor, placental growth factor, and soluble VEGF receptor 1. The interassay and intra-assay coefficient of variation are less than 12% as specified by the manufacturer.
Statistical analysis. The data are presented as means Ϯ SE. Oneway ANOVA following post hoc Student-Newman-Keuls test was used to determine the difference among multiple groups. A P value Ͻ0.05 was considered as statistically significant.
RESULTS

DHT, but not 17␤-estradiol, produced a dose-and timedependent induction of cell proliferation in primary HAECs.
To determine whether androgens affect cell proliferation in HAECs, treatment of HAECs with various doses of DHT or Table 1 .
Primers used for real-time qRT-PCR
Gene Primers AR Forward: 5=-AGGATGCTCTACTTCGCCCC-3= Reverse: 5=-ACTGGCTGTACATCCGGGAC-3= Cyclin A Forward: 5=-TGGACCTTCACCAGACCTAC-3= Reverse: 5=-GGTTGAGGAGAGAAACACCA-3= Cyclin D1
Forward: 5=-AGGAGAACAAACAGATCATCCG-3= Reverse: 5=-GAGGGCGGATTGGAAATGAACT-3= GAPDH Forward: 5=-GAAGGTGAAGGTCGGAGTC-3= Reverse: 5=-GAAGATGGTGATGGGATTTC-3= VEGF-A Forward: 5=-CGAAGTGGTGAAGTTCATGGATG-3= Reverse: 5=-TTCTGTATCAGTCTTTCCTGGTGAG-3=
AR, androgen receptor; VEGF-A, vascular endothelial growth factor-A.
testosterone for 1 or 2 days was carried out. As shown in Fig. 1 , treatment with DHT at doses ranging from 1 to 50 nmol/l for 24 to 48 h produced a dose-and time-dependent induction of cell proliferation as evident by the increase in viable cell number. At 24 h of DHT treatment, the viable cell number was increased by ϳ13.1%, 16.8% (P Ͻ 0.05), 18.3% (P Ͻ 0.05), and 12.7% compared with control at doses of 1, 5, 10, and 50 nmol/l, respectively. At 48 h of DHT treatment, the viable cell number was increased by ϳ16.6%, 19.7%, 20.7% (P Ͻ 0.05), and 25.3% (P Ͻ 0.05) compared with control at doses of 1, 5, 10, and 50 nmol/l, respectively (Fig. 1A) . Treatment with testosterone at doses ranging from 0.5 to 50.0 nmol/l produced a similar time-and dose-dependent induction of cell proliferation, and the viable cell number was significantly increased at 10 and 50 nmol/l of testosterone for 48 h in HAECs (Fig. 1C and data not shown). Moreover, similar DHT induction of cell proliferation was observed in primary HAECs obtained from a second independent source (Invitrogen, Fig. 1D ). In contrast, treatment with 17␤-estradiol at doses raging from 1 to 1,000 nM for either 24 or 48 h failed to significantly alter the cell proliferation in these primary HAECs (Fig. 1B) . Both Lonza and Invitrogen primary HAECs are originated from males based on the information from the vendor and evidenced by the presence of SRY gene using PCR analysis (data not shown).
Because DHT significantly induced cell proliferation in both primary HAECs, all subsequent experiments were performed in primary HAECs obtained form Lonza.
DHT increased multiple gene expression in HAECs.
To determine the effects of DHT on gene expression in HAECs, real-time qRT-PCR was used to determine mRNA levels of AR, cyclin A, cyclin D1 (35) , and VEGF-A (46). At 6, 24, and 48 h, treatment with DHT at 5 nmol/l tends to increase AR mRNA expression by 15%, 25% and 17%, respectively, whereas DHT at 10 nmol/l elevated AR mRNA expression by 47% (P Ͻ 0.05), 59%, and 41% (P Ͻ 0.05), respectively ( Fig. 2A) . Similarly, DHT produced a dose-and time-dependent induction of VEGF-A (Fig. 2C ), cyclin A (Fig. 2E) , and cyclin D1 (Fig. 2F ) mRNA in HAECs. At 48 h of 10 nmol/l DHT treatment, the mRNAs of AR, VEGF-A, cyclin A, and cyclin D1 were moderately but significantly increased by 41%, 53%, 34% and 43% as shown in Fig. 2 , A, C, E, and F, respectively. DHT-induced AR and VEGF-A expression were further analyzed by Western blot to determine cellular AR levels and by electrochemiluminescence to determine VEGF concentration in cell culture media. Treatment with DHT for 48 h resulted in a dose-dependent increase in VEGF concentration in cell culture media (Fig. 2D ) and more than doubled the AR level in HAECs at a 10 nmol/l dose (lane 1 of Fig. 2B, right) .
DHT-induced cell proliferation and gene expression was mediated via an AR-dependent mechanism. To determine whether the DHT actions are mediated via AR in HAECs, cells were cotreated with DHT and casodex, a potent nonsteroidal AR antagonist that blocks AR actions, or with a specific AR siRNA that knocks down the AR level. As shown in Fig. 3 , DHT-induced increases in viable cell number (Fig. 3A) , and DNA biosynthesis (Fig. 3B) in HAECs was completely blocked by the addition of casodex at doses ranging from 1 to 10 mol/l. Similarly, casodex significantly inhibited DHT-induced increases in AR, VEGF-A, and cyclin A mRNA in HAECs at either 6 or 48 h (Fig. 4, A-C) . Although casodex attenuated DHT-induced increase in cyclin D1 mRNA at 48 h, the decrease was not statistically significant because of small sample size (Fig. 4D) . Of note, casodex also slightly elevated the cyclin D mRNA level at 48 h although not with statistical significance. The DHT-induced increase in VEGF concentration in culture media was also completely blocked by casodex (Fig. 4E) .
To examine the role of AR in DHT induction of cell proliferation further, a specific AR siRNA was transfected to the HAECs to silence AR gene expression. The transfection of a specific AR siRNA (100 or 200 nmol/l), but not a protein kinase C␦ or a nonspecific siRNA, in HAECs almost completely knocked down the AR expression at 72 h of transfection as demonstrated by Western blot analysis (lane 2 of Fig. 2B ). Meanwhile, DHTinduced DNA biosynthesis (Fig. 3D) and DHT-induced increase in medium VEGF level (Fig. 4F ) at 48 h were completely blocked by the specific AR siRNA but not a nonspecific siRNA. However, the DHT induction of viable cell number was only partially attenuated from 32% in no siRNA group to 22% in AR siRNA (200 nM) group as a result of a substantial decrease in viable cell number in AR siRNA-transfected cells (Fig. 3C) . The reason for this AR siRNA-induced decrease in viable cells remains to be investigated. However, it suggests that AR may play a role in cell survival and that residual amount of AR may be still functional in DHT stimulation of cell growth.
DHT-induced cell proliferation was inhibited by decreasing VEGF expression or blocking VEGF action. Because DHT produced a dose-and time-dependent induction of VEGF-A gene expression (Fig. 2D) , and VEGF is a major growth factor of endothelial cells, the functional importance of VEGF in DHT induction of cell proliferation was evaluated in HAECs. Coadministration of SU5416 (semaxanib), a selective synthetic inhibitor of the VEGF receptor, at doses ranging from 1 to 1,000 nmol/l resulted in a dose-dependent inhibition of DHTinduced increases in viable cell number (Fig. 5A ) and DNA biosynthesis (Fig. 5B ) at 48 h of treatment. SU5416 treatment at 48 h also significantly attenuated DHT-induced cyclin A mRNA in a dose-dependent manner (Fig. 6C) . However, it did not significantly alter DHT induction of AR mRNA, VEGF-A mRNA, cyclin D1 mRNA, and medium VEGF concentration as shown in Fig. 6, A, B, D , and E, respectively. The values of VEGF concentrations in culture media as determined by an electrochemiluminescence method in E and F are the means Ϯ SE of 6 individual samples from 2 independent triplicate experiments. The dotted line in E and F denotes the detection limit of the assay. The DHT-induced increase in VEGF level in culture media was blocked by the addition of casodex (E), a specific AR and VEGF siRNA, but not a nonspecific siRNA (F). *P Ͻ 0.05 and **P Ͻ 0.01 compared with corresponding vehicle control; and #P Ͻ 0.05 compared with correspond 10 nmol/l DHT treatment without casodex.
To evaluate the importance of VEGF in DHT-induced cell proliferation further, a specific VEGF siRNA was transfected to HAECs to knock down VEGF expression. The transfection of a specific VEGF siRNA at doses from 100 to 200 nmol/l completely blocked the DHT-induced increases in viable cell number (Fig. 5C ) and BrdU incorporation (Fig. 5D ) as well as DHT-induced VEGF increase in cell culture media (sixth bar from the left of Fig. 4F ). In contrast, the transfection of a nonspecific siRNA had no significant effects on DHT induction of cell culture medium VEGF level (Fig. 4F) , viable cell number (Fig. 5C) , and BrdU incorporation (Fig. 5D) . However, the levels of VEGF in all culture media without DHT treatment were undetectable (Fig. 4F) .
DHT-induced cell proliferation and VEGF expression was blocked by roscovitine. Because DHT increases cyclin (A and D1) gene expression (Fig. 2) via interacting with AR (Fig. 4, C  and D) , and cyclin-cyclin-dependent kinase (CDK) activity plays a significant role in cell proliferation (35) , whether cyclin-CDK activity is involved in DHT-induced cell proliferation in primary HAECs was assessed in the present study. Coadministration of roscovitine, a specific CDK inhibitor, at either 1 or 10 mol/l concentration, significantly inhibited DHT-induced increases in viable cell number (Fig. 7A ) and BrdU incorporation (Fig. 7B) . Interestingly, roscovitine selectively inhibited DHT-induced upregulation of VEGF-A mRNA (Fig. 7D ) at 48 h and AR mRNA at 6 h (Fig. 7C ) without significant blockade of DHT-induced increases in AR (Fig. 7C), cyclin A (Fig. 7E) , and cyclin D mRNA (Fig. 7F ) at 48 h in HAECs. The reason for roscovitine inhibition of DHT induction of AR mRNA at 6 h but not at 48 h is unknown and remains to be investigated.
DISCUSSION
Recently, there is growing evidence to support that androgens display beneficial effects on protection of the cardiovascular system (7, 28, 33) . Among various mechanisms, a po- tential mechanism of androgen beneficial effects on cardiovascular function is by modulating endothelial cell function. Endothelial cells participate in vascular homeostasis and in a variety of physiological or pathological processes. The integrity of endothelium is the initiating step for the development of the functional vascular network (30) . Accumulative studies indicate that the arterial endothelial disorder is involved in the pathogenesis of primary hypertension and atherosclerosis, not only in initiation, but also in sustainment (22, 38) . In the present study, we have demonstrated that androgens, mainly DHT, via interacting with AR stimulate endothelial cell proliferation mediated through upregulation of VEGF and cyclin A gene expression. This androgen-induced endothelial cell proliferation should assist the repair of endothelial injury/ Fig. 6 . DHT-induced gene expression was modulated by a specific VEGFR inhibitor (SU5416). HAECs seeded in 96-well plates were treated with a vehicle control or DHT (10 nmol/l) in the presence or absence of 10 or 100 nM of SU5416 for either 6 or 48 h as indicated. The mRNA levels (A-D) quantitated by real-time qRT-PCR are expressed as fold of corresponding vehicle control group, and the values are the means Ϯ SE of 3-4 independent experiments. The values of VEGF concentrations in culture media as determined by an electrochemiluminescence method (E) are the means Ϯ SE of 6 individual samples from 2 independent triplicate experiments. The dotted line in E denotes the detection limit of the assay. *P Ͻ 0.05 and **P Ͻ 0.01 compared with corresponding vehicle control; and #P Ͻ 0.05 and ##P Ͻ 0.01 compared with corresponding 10 nmol/l DHT treatment without SU.
damage and maintain the endothelium homeostasis. These data provide additional evidence that androgens at their physiological concentrations may possess beneficial actions in cardiovascular system. This in vitro action of androgens may also imply in vivo as androgens have been shown to play a role in neovascularization in animal experiments (42) . The circulating levels of endothelial progenitor cells/endothelial cells are inversely related to cardiovascular disease risks (53) , and they are decreased in subjects with androgen deficiency (11) . Taken together, these data suggest that the effects of androgens on endothelial cells may play a significant role in cardiovascular homeostasis.
It is worthy to note that the administration of 17␤-estradiol with a wide range of concentrations failed to alter cell proliferation in these primary HAECs (Fig. 1B) . Previous studies have shown that estrogen produces variable effects on endothelial cell growth (24) . In HUVECs, estrogen has been reported to produce either stimulatory, inhibitory, or no effect on cell growth (6, 31, 32, 44) . The reason for this discrepancy is not known. In addition to the variation in estrogen doses, a major factor to be considered is the originality of these HUVECs, whether these cells are derived from males or females. The HAECs used in our present study are derived from males on the basis of the information from the vendors and the presence of SRY gene (our unpublished data). Whether the sex steroid action in endothelial cells is sex specific and what the mechanism is remain to be elucidated.
Androgens generally display the actions via a genomic or a nongenomic pathway (29, 57) . In the genomic pathway, androgens bind to intracellular AR, forming a ligand-receptor complex. This complex translocates to nucleus, interacts with cognate DNA response elements of target genes, and regulates target gene expression and subsequently cellular functions. The results obtained in the present study indicate that androgeninduced, i.e., DHT-induced, cell proliferation in HAECs is mediated through interaction with AR to regulate such target gene expression as VEGF, cyclin A, and cyclin D1 (see Fig. 8 ). First, AR is expressed in HAECs as evident by the Western blot demonstration of AR protein (Fig. 2B ) and real-time RT-PCR demonstration of AR mRNA ( Fig. 2A) . Second, the DHT effects on both gene expression and cell proliferation are completely blocked by a specific AR antagonist, casodex (see Figs. 3 and 4) . Third, the DHT-induced cell proliferation (Fig. 3) and gene expression such as VEGF (Fig. 4F) are inhibited by knocking down AR using a specific AR siRNA.
These data are in agreement with previous demonstration in human umbilical endothelial E304 cells in which DHT dose dependently enhanced [ 3 H]thymidine incorporation via interaction with intracellular AR (45) . Although an auto-upregulation of AR expression by DHT may suggest an androgen action via the genomic pathway as previously proposed (26) , further studies are necessary to differentiate the genomic or nongenomic DHT action in these primary HAECs.
Our present study also demonstrates that VEGF is a major mediator of androgen-induced cell proliferation in HAECs (Fig. 8) . VEGF, a subfamily of growth factors, is an essential catalyst promoting endothelial cell proliferation, initiating angiogenic sprouting and creating vascular structures (10) . Of the various VEGFs including VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-F, and placental growth factor, VEGF-A is the most important one in mediating endothelial cell proliferation (10) . VEGFs interact with a set of cellular membrane tyrosine-kinase receptors, including VEGFR1 (Flt-1), VEGFR2 (KDR, Flk-1), and VEGFR3. VEGFR2 is the main receptor with the ability to induce endothelial cell proliferation and migratory and sprouting activity and to promote endothelial cells to form tubule-like structures (12) . It is also the major receptor to mediate VEGF-A actions in endothelial cells although VEGF-A also binds to VEGFR1 (8) . Consistent with previous reports in prostate endothelial cells (40) , prostate epithelial PNT1 cells (46) , prostate fetal fibroblast and dermal papilla cells (23) , DHT acting on AR also induced VEGF-A gene expression in HAECs in a time-and dose-dependent manner (see Figs. 2 and 4) . This DHT-induced VEGF-A gene expression is crucial for DHT induction of cell proliferation as the knockdown of DHT-induced VEGF-A expression using a specific VEGF-A siRNA completely blocks DHT stimulation of cell proliferation (see Fig. 5 ). Furthermore, coadministration of SU5416, a specific VEGFR inhibitor with a high affinity to VEGFR2 (IC 50 of VEGFR1 around 0.2 mol/l and IC50 of VEGFR2 about 0.08 mol/l) (54), results in a dose-dependent inhibition of DHT induction of cell proliferation (see Fig. 5 ), indicating that DHT-induced VEGF interacts with VEGFRs, mainly VEGFR2, to stimulate HAEC proliferation (Fig. 8) . This result is in parallel with the report that DHT regulation of VEGF-A expression in prostate endothelial cells involves the androgenic regulation of prostate blood flow (40) . Taken together, these data support that VEGFA regulated by androgens is a major mediator of androgen actions on endothelial cell proliferation.
Regulation of the cell cycle plays an essential role in cell proliferation, differentiation, and cell death (17, 34) . The cell cycle, consisting of G1, S, G2, and M phase, is controlled by the sequential activation of CDKs upon association with their partner cyclins, and, therefore, regulation of cyclin-CDK complexes is a promising junction to regulate cell proliferation (35, 39) . Both cyclin A and cyclin D1 are key regulators in cell cycle progression especially for cells to enter into S phase (see Fig. 8 ). Cyclin A interacting with CDK1 and CDK2 triggers the S and G2 phases, whereas cyclin D1 binds to CDK4 and CDK6 to promote cell cycle from G1 to S phase in the cell (3, 17, 35) . It has been shown in prostate tumor cells that androgens via AR directly regulate the expression of cyclins and then stimulate cell proliferation (14, 35, 60) . In the present study, we have shown that treatment with DHT in HAECs results in a time-and dose-dependent induction of cyclin A and D1 expression (Fig. 2) . The functional significance of cyclin-CDK activity in DHT-induced cell proliferation was evaluated using roscovitine, a specific CDK-inhibitor with a relatively higher affinity to CDK1 (IC 50 ϭ 0.65 mol/l) and CDK2 (IC 50 ϭ 0.7 mol/l), but not active against CDK4 (IC 50 Ͼ1000 mol/l) (3). Coadministration of roscovitine at either 1 or 10 mol/l completely blocked DHT-induced increases in viable cell number and BrdU incorporation in HAECs (Fig. 7) , suggesting that DHT-induced cell proliferation is mediated, at least in part, through the regulation of cyclin-CDK activity in HAECs.
It is worth noting that roscovitine inhibits DHT-induced VEGF-A gene expression without significant alterations in DHT-induced AR, cyclin A, and D1 expression at 48 h of treatment (see Fig. 8 ), indicating that DHT induction of VEGF-A gene expression is dependent on cyclin-CDK activity. This observation is in agreement with a report by Wegiel et al. that cyclin A1, in coordination with Rb (retinoblastoma protein) and AR, is required for androgen induction of VEGF expression in prostate cancer cells (52) . Additionally, Masayoshi et al. have observed that knockdown of cyclin D1 with a specific siRNA results in a decrease in VEGF expression in human colon DLD1 cells and HUVECs, leading to an inhibition of cell proliferation and vessel formation (56) . In sum, these observations suggest that the regulation of VEGF expression by androgens in HAECs is somehow dependent, at least in part, on cyclin-CDK activity although the molecular pathway remains to be elucidated.
On the other hand, SU5416, a specific VEGFR blocker, selectively inhibited DHT induction of cyclin A mRNA (see Fig. 6 ), indicating that DHT-induced cyclin A expression is dependent on VEGF-VEGFR interaction. Taking the observations of roscovitine and SU5416 experiments together, it is suggestible that there is a loop system among androgeninduced VEGF and cyclin A expression in HAECs (Fig. 8) although the detail relationship and the significance of this loop system remain to be further investigated.
In summary, the present study demonstrates that androgens, mainly DHT, acting on AR stimulate HAEC proliferation at their physiological concentrations probably through regulation of VEGF-A, cyclin A, and cyclin D1 expression although the upregulation effects are moderate. The stimulation of endothelial cell proliferation in cardiovascular system should assist the repair of endothelial injury/damage, preventing endothelium dysfunction, a primary risk factor of vascular stiffness, hypertension, and atherosclerosis. Further elucidation of androgen actions in endothelial cells will likely facilitate our understanding of beneficial androgen functions in cardiovascular system and promote the translation of androgen application in the prevention and therapy of cardiovascular diseases in androgendeficient subjects such as hypogonadal men and elders.
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